|本期目录/Table of Contents|

[1]李 想,丁江华,李起栋.心率减速力与表阿霉素所致心肌损伤的相关性分析[J].医学研究与战创伤救治(原医学研究生学报),2015,17(06):587-590.[doi:10.3969/j.issn.1672-271X.2015.06.008]
　LI Xiang,DING Jiang-hua,LI Qi-dong..Relative analysis of between deceleration capacity of heart rate and epirubicin-induced cardiotoxicity[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(06):587-590.[doi:10.3969/j.issn.1672-271X.2015.06.008]
点击复制

心率减速力与表阿霉素所致心肌损伤的相关性分析()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第17卷
期数:
2015年06期
页码:
587-590
栏目:
出版日期:
2015-12-15

文章信息/Info

Title:
Relative analysis of between deceleration capacity of heart rate and epirubicin-induced cardiotoxicity
作者:
李 想1; 丁江华2; 李起栋1
332000 江西九江，南京军区庐山疗养院（解放军171医院）,1.心血管内科（李想为赣南医学院2011级临床医学系实习医师）,2. 血液肿瘤科
Author(s):
LI Xiang1;  DING Jiang-hua2;  LI Qi-dong1.
1.Department of Cardiovasology, 2.Department of Haematology, Lushan Sanatorium of Nanjing Military Command (171 Hospital of PLA), Jiujiang, Jiangxi 332000， China
关键词:
心率减速力; 表阿霉素; 心肌损伤
Keywords:
deceleration capacity of heart rate;  epirubicin;  cardiotoxicity
分类号:
R541
DOI:
10.3969/j.issn.1672-271X.2015.06.008
文献标志码:
A
摘要:
目的 探讨心率减速力（deceleartion capacity of heart rate,DC）对血液系统肿瘤患者中表阿霉素所致心肌损伤的预测价值。方法 纳入40例接受含表阿霉素方案治疗的血液系统肿瘤患者（非何杰金淋巴瘤26例，多发性骨髓瘤14例），所有患者均于化疗前、化疗2周期、4周期与6周期后行动态心电图与超声心动图检查，分析DC值与高血压病史、化疗周期数及左室射血分数（LVEF）的相关性。结果 ①在有高血压组，化疗前、化疗6周期的DC值异常率（DC≤4.5 ms）明显高于无高血压组（P＜0.05）；无论有无高血压情况，化疗6周期后患者DC值均明显低于化疗前（P＜0.05）；②与化疗前相比，化疗4、6周期后的DC值异常率明显增高（P＜0.05）；化疗2、6周期后的DC值异常率有明显差异（P＜0.05）；③化疗6周期后，有高血压组的DC值明显低于无高血压病（P＜0.05），但LVEF值却无明显差异（P＞0.05）；④在有或无高血压病组，化疗6周期后两组的DC与LVEF之间均呈正相关（r分别为0.81与0.84，P＜0.05）。结论 在血液系统肿瘤中，DC值下降可作为表阿霉素蓄积性心脏毒性的指标，且较LVEF更早提示心肌损伤，高血压病史可作为表阿霉素心脏毒性的加重因素。
Abstract:
Objective To explore the prediction role of deceleration capacity of heart rate (DC) in patients with hematological malignancies treated with epirubicin-based regimen. Methods 40 consecutive patients received the treatment of the epirubicin-based regimen, i.e. 26 with non-Hodgkin leukemia, 14 with multiple myeloma. The dynamic electrocardiogram and ultrasonic cardiogram were examined in all patients before the initial chemotherapy and after the 2th, 4th, and 6th chemotherapy. The DC was designed as abnormal when DC ≤4.5 ms. The correlations of DC with the history of hypertension, the chemotherapy cycles and left ventricular ejection fraction (LVEF) were analysed. Results ①The abnormal rate of DC in patients with hypertension was higher than that in patients without hypertension both before and after 6 cycles of chemotherapy (P＜0.05). At the 6th chemotherapy, the patients with or without hypertension possessed higher rate of abnormal DC when compared with patients without chemotherapy (P＜0.05). ②The abnormal rate of DC was markedly higher in patients accepting 4, 6 cycles of chemotherapy in comparison with the baseline(P＜0.05). Significant difference of the DC existed in patients between the 2nd and 6th chemotherapy(P＜0.05). ③When treated with 6 cycles of chemotherapy, the patients with hypertension exhibited lower DC in comparison with patients without hypertension(P＜0.05). No significant difference of LVEF was observed between the two groups(P>0.05). ④The DC was positively associated with LVEF in the group with or without hypertension when treated with 6 cycles of chemotherapy(r=0.81,0.84; P＜0.05). Conclusion In patients with hematological malignancies, the decrease of DC may be regarded as the prognostic index of accumulative cardiotxicity from epirubicin and indicate the earlier myocardial damage when compared with LVEF. The history of hypertension may increase the cardiotoxicity when patients received epirubicin treatment.

参考文献/References:

[1] 徐永茂，徐冬云，张南征，等. 肝动脉栓塞化疗联合冷循环微波凝固治疗大肝癌40例[J]. 东南国防医药，2011,13(5): 446-447. [2] 李 茜，张文杰，马巧珍，等. 参麦注射液治疗阿霉素致心脏毒性的心电图观察[J]. 东南国防医药，2008,10(1): 43-45. [3] Vasti C, Hertig CM. Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines[J]. World J Cardiol, 2014, 6(7): 653-662. [4] Wang YP, Kuo TB, Lai CT, et al. Effects of breathing frequency on the heart rate deceleration capacity and heart rate acceleration capacity[J]. Eur J Appl Physiol, 2015.doi: 10.1007/s00421-015-3219-4. [Epub ahead of print] [5] Ricca-Mallada R,Migliaro ER,Piskorski J,et al. Exercise training slows down heart rate and improves deceleration and acceleration capacity in patients with heart failure[J]. J Electrocardiol, 2012, 45(3): 214-219. [6] 张之南，沈 悌. 血液病诊断及疗效标准[M]. 3版.北京:科学出版社, 2007: 220-232. [7] 闫鹏丽，王 林，吴存瑾，等. 从最新中国高血压指南分析门诊用药规范性[J]. 天津医药, 2014,42(5): 498-501. [8] 周剑峰，孙汉英，张义成. 血液病诊疗指南[M]. 3版.北京:科学出版社, 2013: 230-286. [9] Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study[J]. Lancet, 2006, 367(9523): 1674-1681. [10] 徐春芳，黄 芬，杨晓云，等. 急性脑梗死伴高血压患者的心率减速力与心率变异性研究[J]. 中国心脏起搏与心电生理杂志, 2015,29(2): 139-142. [11] Bauer A, Morley-Davies A, Barthel P, et al. Bivariate phase-rectified signal averaging for assessment of spontaneous baroreflex sensitivity: pilot study of the technology[J]. J Electrocardiol, 2010, 43(6): 649-653. [12] 郭继鸿. 心率减速力检测[J]. 临床心电学杂志, 2009,18(1): 59-68. [13] 张志敏，杜国峰. 中老年高血压患者的心率减速力研究[J]. 实用老年医学, 2014,28(3): 248-250. [14] 吴志忍，林 荣，吴 兵. 心率减速力与连续心率减速力对急性心肌梗死患者预后的影响[J]. 解放军医学院学报, 2013,34(12): 1242-1245. [15] 王兴德，韩晓勤. 慢性心力衰竭患者心率减速力检测的临床意义[J]. 临床心电学杂志, 2012,21(6): 422-424. [16] 俸艳英，阳志军，彭 旭，等. 心率减速力检测在预测表阿霉素心脏毒性中的临床应用价值[J]. 中国肿瘤临床, 2015,42(13): 648-652. [17] Mancia G, Grassi G. The autonomic nervous system and hypertension[J]. Circ Res, 2014, 114(11): 1804-1814. [18] 张志敏，杜国峰. 高血压患者心率减速力与室性心律失常[J]. 临床心电学杂志, 2014,23(2): 91-93. [19] Szmit S, Jurczak W, Zaucha JM, et al. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma[J]. J Am Soc Hypertens, 2014, 8(11): 791-799. [20] Feng YY, Yang ZJ. The clinical application of the heart rate deceleration capacity test to predict epirubicin-induced cardiotoxicity[J]. J Cardiovasc Pharmacol, 2015. doi:10.1097/FJC.00000000000 00289 [Epub ahead of print] [21] Patane S. Cardiotoxicity: anthracyclines and long term cancer survivors[J]. Int J Cardiol, 2014, 176(3): 1326-1328. [22] 周京敏，崔晓通. 左心室射血分数保存的心力衰竭研究进展[J]. 内科理论与实践, 2014,9(1): 1-7. [23] Buccheri S, Costanzo L, Tamburino C, et al. Reference values for real time three-dimensional echocardiography-derived left ventricular volumes and ejection fraction: review and meta-analysis of currently available Studies[J]. Echocardiography, 2015.doi: 10.1111/echo.12972 [Epub ahead of print]

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2015-11-20